Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
Tags :Pauline Pfirter
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based start-up that is researching a therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the
Vischer acted as legal counsel for Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), on the closing of its CHF 18 million seed round. The financing was led
The team was led by Matthias Staehelin (pictured) and Moritz Jäggy with Sebastian Flückiger and Pauline Pfirter (all Corporate). Partners David Rosenthal (Data Privacy) and Nadia Tarolli (Tax) assisted as well.
Walder Wyss advises Boehringer Ingelheim. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured left) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital). VISCHER advised
VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included
VISCHER advises T3 Pharmaceuticals on all legal issues in connection with the transaction. The team consists of Christian Wyss (Partner, Corporate / M&A - pictured), Pauline Pfirter (Associate, Corporate / M&A), Ruben Masar (Associate, Corporate /
The Yverdon-based company for multi-material cutting tools, Lamina Technologies, was taken over by Triton via its Triton Smaller Mid Cap Fund (TSM).
